Eli Lilly ( LLY 0.89%) has been growing its sales at a good clip over the past year. This is partly thanks to Zepbound, a ...

On Tuesday, the stock fell by 8% after the company forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street estimates. The stock has gained 434.64% over the last 5 years ...

Key takeaways Eli Lilly has filed lawsuits against four telehealth companies—Mochi Health, Fella Health, Willow Health, and ...

Earlier this week, Lilly raised its earnings forecasts as well, on the back of rising sales of Zepbound and diabetes therapy Mounjaro, also based on tirzepatide, saying it was seeing the benefit ...

The F.D.A. ordered compounding for versions of Eli Lilly’s Zepbound to end last month. Small compounders have until April 22 to stop making and selling versions of Novo Nordisk’s Wegovy ...

BofA keeps an Underperform rating on Hims & Hers with a $22 price target after the company indicated it is adding a branded version of Eli Lilly’s (LLY) Zepbound to its platform. The firm does ...

Weight loss injections like Ozempic and Zepbound have taken Hollywood and social media by storm over the last year or so. Personally, I've been on Zepbound for nearly 10 weeks now and I've lost ...

BofA on Friday forecast first-quarter sales to come in 1% to 2% below current ... U.S. prescription data for Novo's Wegovy and Lilly's Zepbound. Barclays in a note on Friday said prescriptions ...